Abstracts tagged "chemokines"

Abstract Number: 1139 • 2015 ACR/ARHP Annual Meeting
Differential Inflammatory Profile in Experimental Models of Arthritis
Ana C. Ortiz¹, Anne Crilly¹, Lynette Dunning¹, Carmen Huesa¹, C. S. Goodyear², John C. Lockhart¹, William R. Ferrell² and Iain B. McInnes², ¹Institute of Biomedical and Environmental Health Research, University of the West of Scotland, Paisley, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: While osteoarthritis (OA) in humans is characterized by cartilage degradation, osteophyte formation and joint remodeling, inflammation and synovitis are now recognized to contribute to…
Abstract Number: 1148 • 2015 ACR/ARHP Annual Meeting
The Role of TRPC6 in CXCR2-Mediated Chondrocyte Phenotypic Stability
Joanna Sherwood¹, Jessica Bertrand¹, Francesco Dell'Accio² and Thomas Pap³, ¹Institute for Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, ²EMR, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ³Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: We have recently demonstrated that ELR+ CXC chemokines signaling via the CXCR2 receptor, are produced by healthy chondrocytes and are retained within the cartilage…
Abstract Number: 1361 • 2015 ACR/ARHP Annual Meeting
Synovial Macrophages Promote TGF-β Signaling but Protect Against Influx of S100A8/S100A9-Producing Cells after Intra-Articular Injections of Oxidized Low-Density Lipoproteins
Wouter de Munter¹, Martijn H. van den Bosch¹, Arjen Blom¹, Birgitte Walgreen², Monique Helsen¹, Leo Joosten³, Johannes Roth⁴, Thomas Vogl⁵, Fons van de Loo¹, Marije Koenders¹, Wim van den Berg¹, Peter van der Kraan¹ and Peter van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Internal Medicine, Radboud university medical center, Nijmegen, Netherlands, ⁴Institute of Immunology, University of Münster, Münster, Germany, ⁵University of Muenster, Muenster, Germany
Background/Purpose: In previous studies we found that synovial macrophages regulate joint pathology during experimental osteoarthritis (OA). Recently, we found that high systemic levels of LDL…
Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Edward Stern^1,2, Cassandra Hong², Voon H. Ong², Aine Burns¹, Robert Unwin³ and Christopher P. Denton⁴, ¹Nephrology, Royal Free Hospital, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
Abstract Number: 1964 • 2015 ACR/ARHP Annual Meeting
Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis
Katja Lakota¹, Tadeja Kuret², Polona Žigon¹, Ziga Rotar¹, Matija Tomsic¹, Saša Čučnik^1,2, Snezna Sodin Semrl^1,3 and Alojzija Hocevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, ³Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia
Background/Purpose: Giant cell arteritis (GCA) is a large- and medium- vessel arteritis characterized by a range of histological patterns of vascular wall injury. The temporal…
Abstract Number: 2013 • 2015 ACR/ARHP Annual Meeting
TIARP Attenuates Autoantibody-Mediated Arthritis Via the Suppression of Neutrophil Infiltration into the Joint
Asuka Inoue¹, Isao Matsumoto¹, Yuki Tanaka², Naoto Umeda¹, Hoshimi Kawaguchi¹, Hiroshi Ebe¹, Yoshihiro Matsumoto³ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, University of Tsukuba, Tsukuba, Japan, ³Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: TIARP (TNFα-induced adipose-related protein) is dominantly expressed in macrophages (Mφ), neutrophils (PMN) and fibroblast-like synoviocytes (FLS). Recently, we found that TIARP functions as a…
Abstract Number: 2086 • 2015 ACR/ARHP Annual Meeting
Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis
Lauren A. Jordan¹, Ruth Davies¹, Alastair J. D. Robertson², Ann K. Harvey¹, Ernest H. Choy¹, Malin Erlandsson³, Maria I. Bokarewa⁴, Rachel J. Errington¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²William Harvey Hospital, Willesborough, Ashford, United Kingdom, ³University of Goteborg, Goteborg, Sweden, ⁴Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden
Background/Purpose: The destruction of bone is a common feature of diseases like rheumatoid arthritis (RA) and multiple myeloma (MM). CCL3 is significantly elevated in the…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 2993 • 2015 ACR/ARHP Annual Meeting
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation
Serena Vettori¹, Rosaria Irace², Veronica Giacco², Antonella Riccardi², Lucia Vicedomini², Luciana Pellecchia² and Gabriele Valentini², ¹Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine, that has been shown to be increased in the sera of patients with systemic sclerosis (SSc)…
Abstract Number: 922 • 2014 ACR/ARHP Annual Meeting
A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain
Rachel E. Miller¹, Shingo Ishihara², Phuong Tran³, Richard J. Miller⁴ and Anne-Marie Malfait⁵, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁵Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose - Damage associated molecular patterns (DAMPs) result from cellular stress and extracellular matrix breakdown. They may contribute to osteoarthritis (OA) pathogenesis by promoting synovitis…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 338 • 2014 ACR/ARHP Annual Meeting
Bombina Variegate peptide8/Prokineticin 2: A Novel Arthritis-Inducible Chemokine
Haruyasu Ito, Ken Yoshida, Kentaro Noda and Daitaro Kurosaka, Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by the joint destruction. Chemokines play important roles as monocyte and neutrophil recruiters in RA.…
Abstract Number: 30 • 2014 ACR/ARHP Annual Meeting
Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14^+VE Monocultures Reduces Osteoclast Differentiation
Lauren A. Jordan¹, Fraser L. Collins², Simon A. Jones¹, Ernest H. Choy³, Ann K. Harvey¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom, ²Michigan State University, Department of Physiology, East Lansing, MI, ³Section of Rheumatology, Cardiff University, Institute of Infection and Immunity, School of Medicine, Cardiff, United Kingdom
Background/Purpose: Interleukin-6 (IL-6) and the inflammatory CC-chemokine CCL3 are highly expressed in rheumatoid arthritis, juvenile idiopathic arthritis and multiple myeloma. While these mediators contribute to…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].